With the start of January, many individuals are preparing to kick off the New Year by setting new health and fitness objectives, which often include weight loss goals. While regular exercise, gym visits, and a well-balanced diet play crucial roles in enhancing overall well-being and aiding weight loss, some may find these efforts insufficient.
Certain medications, such as GLP-1 agonists like tirzepatide and semaglutide (known by brand names like Mounjaro, Ozempic, or Wegovy), can assist in triggering weight loss. These medications are typically recommended for individuals with type 2 diabetes or those struggling to lose weight through lifestyle changes alone. They serve as a supportive tool for individuals facing challenges in weight management despite other efforts.
GLP-1 agonists function by delaying food digestion, mimicking gut hormones to regulate blood sugar levels, and curbing appetite. Patients eligible for these injections, prescribed by a healthcare provider, should be aware of an important NHS alert. This alert specifically concerns individuals concurrently taking other medications, such as the contraceptive pill and Hormone Replacement Therapy (HRT).
The NHS has issued a caution on its website directed at patients using weight loss injections alongside the pill or HRT, warning that these injections may impact the effectiveness of the pill and HRT. For instance, tirzepatide (Mounjaro) might reduce the efficacy of oral contraceptives, including the Progesterone-Only Pill. In such cases, additional protection, like condoms, is advised in situations like vomiting or diarrhea.
Regarding Semaglutide and similar medications, the NHS mentions that they do not seem to diminish the pill’s effectiveness. Nonetheless, side effects such as vomiting or diarrhea can affect pill absorption. Therefore, using extra protection and following specific guidelines in case of vomiting or diarrhea is recommended.
The NHS emphasizes that GLP-1 agonists do not interfere with non-oral contraception methods like the coil (IUD), implant, or injection. Patients considering changing their contraceptive method while using a GLP-1 agonist should consult their physician.
It is crucial not to use GLP-1 agonists during pregnancy, and effective contraception is essential while taking these medications. If pregnancy occurs during this treatment, immediate consultation with a doctor is necessary, and discontinuing GLP-1 agonists several weeks before attempting to conceive is advised.
Patients taking HRT with progesterone tablets should be cautious as medications like Tirzepatide (Mounjaro) and Semaglutide may impact tablet absorption, potentially leading to irregular bleeding or affecting womb lining protection. Patients are urged to contact their healthcare provider to discuss suitable HRT or contraception options while using weight loss medication.